Efficacy of the apitherapy in the treatment of recalcitrant localized plaque psoriasis and evaluation of tumor necrosis factor-alpha (TNF-α) serum level: A double-blind randomized clinical trial

J Dermatolog Treat. 2015;26(4):335-9. doi: 10.3109/09546634.2014.990411. Epub 2014 Dec 30.


Background: No universal consensus about optimal modality for treating the recalcitrant localized plaque psoriasis (RLPP) is available.

Objective: To evaluate the immunological and clinical therapeutic effect of using apitherapy in the treatment of RLPP.

Methods: Randomized 50 patients with RLPP received apitherapy (n = 25) and placebo (n = 25) every week. Both treatments were injected into lesions at weekly intervals for a maximum of 12 treatments. Following up was 6 months later. Tumor necrosis factor-alpha (TNF-α) level was measured at pre-study and at 12th week.

Results: A significant difference was found between the therapeutic responses of RLPP to the apitherapy and placebo groups (p<0.001). In the apitherapy group, complete response was achieved in 92% of patients. There was statistically significant decrease in TNF-α in the apitherapy group compared to the placebo group. No recurrence was observed in the apitherapy group.

Conclusion: Apitherapy is effective and a safe treatment for recalcitrant localized plaque psoriasis, when other topical or physical therapies have failed.

Keywords: Apitherapy; PGA; TNF-α; bee venom; recalcitrant localized plaque psoriasis.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Apitherapy / methods*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Psoriasis / therapy*
  • Remission Induction
  • Tumor Necrosis Factor-alpha / blood*
  • Young Adult


  • Tumor Necrosis Factor-alpha